Email this article ENGINEERING OF ATTENUATED BORDETELLA PERTUSSIS BACTERIA PRODUCING IMMUNOGENIC NON-TOXIC FORM OF PERTUSSIS TOXIN
- Authors: Sinyashina L.N1, Nechaeva E.V1, Amelina I.P1, Karataev G.I1
-
Affiliations:
- Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia
- Issue: Vol 86, No 6 (2009)
- Pages: 89-94
- Section: Articles
- URL: https://microbiol.crie.ru/jour/article/view/13370
- ID: 13370
Cite item
Full Text
Abstract
Aim. To engineer attenuated Bordetella pertussis strain producing non-toxic immunogenic derivative of pertussis toxin (toxoid KT). Materials and methods. Cloning, site-directed mutagenesis, allelic exchange as well as methods for determination of immunobiological characteristics of toxoid KT were used. Results. Attenuated B.pertussis strains 5 and 35 containing mutant operon ptx and gene of resistance to canamycin were engineered. Recombinant bacteria retained marker of resistance to canamycin as well as structure of mutant operon during cultivation on growth media and long-term survival in lung of laboratory mice. Immunobiologic characteristics of attenuated B.pertussis were studied. Conclusion. Intranasal immunization of laboratory animals with live attenuated B.pertussis 5 and 35 provides protection from infection with virulent B.pertussis strain, which is comparable with efficacy of standard whole-cell vaccine.
Full Text
КОНСТРУИРОВАНИЕ АТТЕНУИРОВАННЫХ БАКТЕРИЙ ВORDETELLA PERTUSSIS, ПРОДУЦИРУЮЩИХ ИММУНОГЕННУЮ НЕТОКСИЧНУЮ ФОРМУ КОКЛЮШНОГО ТОКСИНА×
About the authors
L. N Sinyashina
Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia
E. V Nechaeva
Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia
I. P Amelina
Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia
G. I Karataev
Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia
References
- Говорун В.М., Иванова В.Ф., Кириллов М.Ю. и др. Особенности экспрессии оперона коклюшного токсина под контролем собственного и гетерологичного промоторов в клетках B.bronchiseptica. Мол. генет. микробиол. вирусол. 1993, 2: 21-27.
- Маниатис Т., Фрич Э., Сэмбрук Дж. Молекулярное клонирование. М., Мир, 1984.
- Миллер Дж. Эксперименты в молекулярной генетике. М., Мир, 1984.
- Шинкарев А.С., Мерцалова Н.У., Мазурова И.К. и др. Современные штаммы B.pertussis: иммунобиологические свойства и совершенствование вакцины. Журн. микробиол. 2007, 4:20-25.
- Guiso N., Njamkepo E., Vié le Sage F. et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favorably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine. 2007, 25: 1390-13907.
- Mattoo S., James D. Molecular pathogenesis, epidemiology and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 2005, 18: 326-382.
- Mielcarek N., Debrie A-S., Raze D. et al. Live attenuated B.pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathogens. 2006, 2: 0662-0670.
- Mooi F. R., van Loo I.H., King A.J. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg. Infect. Dis. 2001, 7: 526-528.
- Pizza M., Covacci A., Bartoloni A. et al. Mutants of pertussis toxin sutable for vaccine development. Science. 1989, 246: 497-500.
- Purdy K.W., Hay J.W., Botteman M.F., Ward K. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin. Infect. Dis., 2004, 39: 29-30.
- Stevenson A., Roberts M. Use of B.bronchiseptica and B.pertussis as live vaccines and vectors for heterologous antigen. FEMS Immunol. Med. Microbiol. 2003, 37: 121-128.
Supplementary files
